Life sciences firm Perseon has sold its hyperthermia technology assets formerly marketed under the BSD Medical brand to Pyrexar Medical.
Medical device industry veteran Mark Falkowski has been named CEO of Pyrexar; he has 30 years of experience acquired with companies such as GE Healthcare, Imatron, Carestream, and OEC/Diasonics.
Falkowski recruited four executives to join industry veterans to create the new company, including Paul Turner, Ray Lauritzen, Richard Faux, Dennis Bradley, and a group of system design, production, and customer support team members. Pyrexar plans to reveal new hyperthermia treatment technologies at the upcoming Society for Thermal Medicine annual meeting in Orlando, FL, to be held April 15-17.
BSD Medical in January announced its plan to exit the hyperthermia business to focus on its MicroThermX microwave ablation technology. The company in February changed its name to Perseon to reflect the new focus.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
